Zynerba sinks after total failure in phase 2 cannabidiol trial | Fierce Biotech
Zynerba Pharmaceuticals Inc Shares Approach 52-Week Low - Market Mover | Nasdaq
Zynerba Pharmaceuticals (ZYNE) - price stock, stock chart, quote online, dividends, stock analysis, stock news, company profile
Zynerba Pharmaceuticals Inc stock soars amid slew of positive drivers
Zynerba Pharmaceuticals (ZYNE) Jumps: Stock Rises 7.7%
Zynerba Pharmaceuticals Inc: CBD Biotech Stock Up 355% In 2019
Zynerba's Stock Forecast for 2021: Is ZYNE a Good Stock to Buy?
Zynerba Pharmaceuticals Stock Quote. ZYNE - Stock Price, News, Charts, Message Board, Trades
Zynerba Pharmaceuticals Inc gets renewed 'Buy' rating, premium $11 price target from Canaccord Genuity after growth conference
Where Will Zynerba Pharmaceuticals Inc (ZYNE) Stock Go Next After It Is Lower By 0.00% in a Week?
Home - Zynerba
Is it Time to Dump Zynerba Pharmaceuticals Inc (ZYNE) Stock After it Is Down 7.02% in a Week?
Zynerba shares surge after Main Line firm wins patent for its CBD gel to treat Autism Spectrum Disorders
Zynerba Pharmaceuticals, Inc. (ZYNE) Company Profile & Overview - Stock Analysis
ZYNE Stock Price Forecast. Should You Buy ZYNE?
Zynerba Pharmaceuticals Stock Is a Cannabis Stock With 700%+ Upside
Zynerba Pharmaceuticals Inc (ZYNE) Stock Price Last Month
Zynerba Stock Price Plummets 51% After CBD Drug Fails Trial
Is Zynerba Pharmaceuticals Inc (ZYNE) Stock a Smart Investment Tuesday?
Zynerba's Stock Forecast for 2021: Is ZYNE a Good Stock to Buy?
